

You are cordially invited to participate...

**Understanding the Role of VASCEPA® (icosapent ethyl) as Add-on to Statins
in Patients With Persistent High Triglyceride Levels (=200 to 500 mg/dL)**

Guest Speaker:

**Peter Gottesfeld, MD
Northern Westchester Family Medicine
Mount Kisco, New York**

**Nina Restaurant
27 West Main Street
Middletown, NY 10940
(845) 344-6800**

**Tuesday, November 17, 2015
6:30 PM**

**Hosted by: Mario Mejorado
(914) 475-8265**

**Please register at: <https://amarin.phoenixgrpmeetings.com>
Click on "Register for a Meeting." Enter code AMA-VAS-2225**

Amarin policy limits attendance at meal functions to physicians, their supporting staff, pharmacists, and medical/pharmacy students. No other guests, including non-practicing spouses, are permitted to attend the program or consume the meal.

Indication and Limitations of Use

VASCEPA® (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

- The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
- The effect of VASCEPA on cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined.

Important Safety Information for VASCEPA

- VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
- Use with caution in patients with known hypersensitivity to fish and/or shellfish.
- The most common reported adverse reaction (incidence $>2\%$ and greater than placebo) was arthralgia.
- Patients receiving treatment with VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.
- In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy.
- Patients should be advised to swallow VASCEPA capsules whole; not to break open, crush, dissolve, or chew VASCEPA.
- Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

See full Prescribing Information for more information on VASCEPA or go to www.vascepa.com.

